MGMT promoter methylation in 1p19q-intact gliomas
ConclusionsThis ancillary analysis supports conclusions from the CATNON trial for adjuvant TMZ as standard-of-care for anaplastic astrocytomas (IDH-mutant and 1p19q-intact), irrespective ofMGMT status. Determining the optimal strategy for diffuse gliomas that are IDH-wildtype will be particularly important.MGMT promoter methylation should be considered as a stratification factor in future clinical trials for these patients.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Astrocytoma | Brain | Brain Tumor | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Databases & Libraries | Glioma | Neurology | Study | Temodar